Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG,Sept. 15,2024-- At the 2024 European Society for Medical Oncology (ESMO) Conference,Akeso released the Phase 2 clinical results